A Novel Class of Exceptionally Potent HIV-1 Protease Inhibitors
- Summary
- Researchers at Purdue University have synthesized a series of exceptionally potent inhibitors for HIV-1 protease, which have been documented as an effective strategy for the treatment of AIDS and HIV. These compounds represent a novel class of HIV-1 protease inhibitors, which have proven to be up to 20-fold more potent than other protease inhibitors on the market.
- Technology Benefits
- Far more potent than other protease inhibitors on the marketGreater potency will significantly reduce dosage requirements Treatment of multidrug-resistant strain of HIV
- Technology Application
- Medical/HealthcareHIV/AIDS Treatment
- Detailed Technology Description
- Arun GhoshGhosh GroupPurdue Chemistry
- Countries
- United States
- Application No.
- 9,024,038
- *Abstract
-
- *Background
- As reported by the World Health Organization (WHO), globally, there were 35.3 million people living with HIV/AIDS in 2012, a number that has been growing due to the increased availability of antiviral treatments. After peaking from 1997 to 2011, the incidence rate has declined nearly 30 percent from 3.5 million to 2.5 million. Within the last 10 years, the availability of antiretroviral therapy and the combination of at least three antiretroviral drugs within low- and middle-income regions has increased nearly 20-fold. In 2010, the global market for HIV/AIDS treatment was valued close to $14 billion and growing, with Gilead Sciences' market-leading protease inhibitor, Atripla, generating revenue of $3.22 billion in 2011.
- *IP Issue Date
- May 5, 2015
- *IP Type
- Cont-in-Part
- *Stage of Development
- Prototype Testing in Economic Run
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry
- Country/Region
- USA
For more information, please click Here
